| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs |  | | 2025 | 56 | 972 |
|
| Case Report : Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation : a case series and literature review | Frontiers in oncology | | | 2025 | 5 | 281 |
|
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | | 2024 | 175 | 1,157 |
|
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | | 2024 | 77 | 253 |
|
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC : A Brief Report | Journal of thoracic oncology | | | 2024 | 49 | 126 |
|
| Rates of febrile neutropenia and its causes in the real world | Future oncology | | | 2024 | 33 | 464 |
|
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | | 2023 | 106 | 68 |
|
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | | 2023 | 54 | 152 |
|
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | | 2023 | 108 | 127 |
|
